Protocol Ledger

NCT06712888 · Phase III · ACTIVE NOT RECRUITING

Toripalimab vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma

Interventional Phase III clinical trial protocol NCT06712888 sponsored by Sun Yat-sen University in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-02-17 Enrollment: 466 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06712888
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)466 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06712888
Protocol FieldVerified Registry Value
NCT IdentifierNCT06712888
Consolidated Lead SponsorSun Yat-sen University
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment466 participants (ACTUAL)
Registered Start Date2025-02-17
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06712888
Hospital Research SiteLocationSite Profile
Fujian Cancer HospitalFuzhou, ChinaOpen Hospital Dossier ->
Sun Yat-sen University Cancer CenterGuangzhou, ChinaOpen Hospital Dossier ->
Hunan Cancer HospitalChangsha, ChinaOpen Hospital Dossier ->
Sichuan Cancer HospitalChengdu, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI